JP2019534321A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534321A5 JP2019534321A5 JP2019537032A JP2019537032A JP2019534321A5 JP 2019534321 A5 JP2019534321 A5 JP 2019534321A5 JP 2019537032 A JP2019537032 A JP 2019537032A JP 2019537032 A JP2019537032 A JP 2019537032A JP 2019534321 A5 JP2019534321 A5 JP 2019534321A5
- Authority
- JP
- Japan
- Prior art keywords
- usp10
- biomarker
- aml
- activity
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000809243 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 10 Proteins 0.000 claims description 167
- 101000748141 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 32 Proteins 0.000 claims description 163
- 102100038426 Ubiquitin carboxyl-terminal hydrolase 10 Human genes 0.000 claims description 163
- 238000000034 method Methods 0.000 claims description 129
- 239000000090 biomarker Substances 0.000 claims description 128
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 83
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 78
- 230000000694 effects Effects 0.000 claims description 78
- 239000003795 chemical substances by application Substances 0.000 claims description 75
- 238000012360 testing method Methods 0.000 claims description 50
- 239000003112 inhibitor Substances 0.000 claims description 46
- 238000002560 therapeutic procedure Methods 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 40
- 239000000523 sample Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 37
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 18
- 102000049850 human FLT3 Human genes 0.000 claims description 18
- 230000003463 hyperproliferative effect Effects 0.000 claims description 17
- 150000003384 small molecules Chemical group 0.000 claims description 16
- 230000030833 cell death Effects 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 10
- 238000010171 animal model Methods 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 230000004083 survival effect Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 4
- 102000053642 Catalytic RNA Human genes 0.000 claims description 4
- 108090000994 Catalytic RNA Proteins 0.000 claims description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 101150020913 USP7 gene Proteins 0.000 claims description 4
- 102100021013 Ubiquitin carboxyl-terminal hydrolase 7 Human genes 0.000 claims description 4
- 108700011958 Ubiquitin-Specific Peptidase 7 Proteins 0.000 claims description 4
- 229940126752 Ubiquitin-specific protease 7 inhibitor Drugs 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 201000002687 childhood acute myeloid leukemia Diseases 0.000 claims description 4
- 239000013068 control sample Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 238000010362 genome editing Methods 0.000 claims description 4
- 102000046976 human USP10 Human genes 0.000 claims description 4
- 238000009396 hybridization Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000002452 interceptive effect Effects 0.000 claims description 4
- 108091070501 miRNA Proteins 0.000 claims description 4
- 239000002679 microRNA Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- -1 piwiRNA Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000003753 real-time PCR Methods 0.000 claims description 4
- 108091092562 ribozyme Proteins 0.000 claims description 4
- 239000002924 silencing RNA Substances 0.000 claims description 4
- 239000004055 small Interfering RNA Substances 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 230000034994 death Effects 0.000 claims description 3
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 210000003608 fece Anatomy 0.000 claims description 2
- 238000012165 high-throughput sequencing Methods 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 238000002493 microarray Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000002626 targeted therapy Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims 1
- 238000013537 high throughput screening Methods 0.000 claims 1
- 101000607909 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 1 Proteins 0.000 description 1
- 102100039865 Ubiquitin carboxyl-terminal hydrolase 1 Human genes 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022094297A JP2022116353A (ja) | 2016-09-20 | 2022-06-10 | Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662397100P | 2016-09-20 | 2016-09-20 | |
| US62/397,100 | 2016-09-20 | ||
| PCT/US2017/052506 WO2018057618A1 (en) | 2016-09-20 | 2017-09-20 | Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022094297A Division JP2022116353A (ja) | 2016-09-20 | 2022-06-10 | Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534321A JP2019534321A (ja) | 2019-11-28 |
| JP2019534321A5 true JP2019534321A5 (https=) | 2020-08-27 |
| JP7466308B2 JP7466308B2 (ja) | 2024-04-12 |
Family
ID=61690641
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537032A Active JP7466308B2 (ja) | 2016-09-20 | 2017-09-20 | Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法 |
| JP2022094297A Pending JP2022116353A (ja) | 2016-09-20 | 2022-06-10 | Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022094297A Pending JP2022116353A (ja) | 2016-09-20 | 2022-06-10 | Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11136409B2 (https=) |
| EP (1) | EP3515559B1 (https=) |
| JP (2) | JP7466308B2 (https=) |
| AU (1) | AU2017332721B2 (https=) |
| CA (1) | CA3034643A1 (https=) |
| ES (1) | ES3033182T3 (https=) |
| WO (1) | WO2018057618A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| US20220125760A1 (en) * | 2019-02-14 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of usp7 inhibitors for the treatment of acute myeloid leukemia (aml) |
| EP3962486A4 (en) | 2019-04-30 | 2023-01-25 | Valo Health, Inc. | ESCAPEMENT OF USP36 |
| US20220281886A1 (en) * | 2019-05-22 | 2022-09-08 | Merck Sharp Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| CN116236580B (zh) * | 2020-02-21 | 2024-05-24 | 中国科学院上海药物研究所 | 金诺芬等老药及其组合物在抗单正链rna病毒中的应用 |
| EP4110393A1 (en) * | 2020-02-28 | 2023-01-04 | Immunologik GmbH | Inhibitors of human deubiquitinases for the treatment of coronaviral infections |
| CN113838206B (zh) * | 2021-09-28 | 2023-05-16 | 南京工业大学 | 一种基于bim的假山瀑布三维设计方法 |
| CN113912595B (zh) * | 2021-10-12 | 2024-03-15 | 中国药科大学 | 一类含有噻唑或噻二唑结构的化合物及其应用 |
| CN114807233B (zh) * | 2022-05-05 | 2023-04-18 | 江苏省人民医院（南京医科大学第一附属医院） | 一种巨噬细胞特异性usp13过表达的重组腺相关病毒及其应用 |
| WO2024097876A1 (en) * | 2022-11-02 | 2024-05-10 | Board Of Regents, The University Of Texas System | Methods relating to optimizing therapy selection for acute myeloid leukemia |
| CN120131695B (zh) * | 2025-03-06 | 2026-02-06 | 浙江大学 | 金诺芬在制备治疗usp6基因重排及异常激活疾病药物中的应用 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US548257A (en) | 1895-10-22 | Hay rake and loader | ||
| US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| ATE117375T1 (de) | 1987-09-11 | 1995-02-15 | Whitehead Biomedical Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
| WO1989005349A1 (en) | 1987-12-09 | 1989-06-15 | The Australian National University | Method of combating viral infections |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| WO1990002806A1 (en) | 1988-09-01 | 1990-03-22 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| CA2489769A1 (en) | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
| EP0834575B1 (en) | 1990-12-06 | 2001-11-28 | Affymetrix, Inc. (a Delaware Corporation) | Identification of nucleic acids in samples |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| EP1134293A3 (en) | 1992-03-04 | 2004-01-07 | The Regents of The University of California | Comparative genomic hybridization (CGH) |
| US5976790A (en) | 1992-03-04 | 1999-11-02 | The Regents Of The University Of California | Comparative Genomic Hybridization (CGH) |
| KR100249110B1 (ko) | 1992-05-06 | 2000-04-01 | 다니엘 엘. 캐시앙 | 핵산 서열 증폭 방법, 이에 이용되는 조성물 및 키트 |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
| AU687010B2 (en) | 1992-07-17 | 1998-02-19 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| DE69433811T2 (de) | 1993-01-07 | 2005-06-23 | Sequenom, Inc., San Diego | Dns - sequenzierung durch massenspektronomie |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| DE4344726C2 (de) | 1993-12-27 | 1997-09-25 | Deutsches Krebsforsch | Verfahren zum Nachweis von nicht balanciertem genetischen Material einer Spezies oder zum Nachweis der Genexpression in Zellen einer Spezies |
| US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
| US6379897B1 (en) | 2000-11-09 | 2002-04-30 | Nanogen, Inc. | Methods for gene expression monitoring on electronic microarrays |
| US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US6465611B1 (en) | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| GB9816781D0 (en) | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
| CA2255430C (en) | 1998-12-10 | 2003-08-26 | P. Wedge Co. Ltd. | A swivel device for a windcone tower assembly |
| EP1390497A2 (en) | 2001-05-25 | 2004-02-25 | Genset | Human cdnas and proteins and uses thereof |
| AU2002355477B2 (en) | 2001-08-03 | 2008-09-25 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
| US20030215858A1 (en) | 2002-04-08 | 2003-11-20 | Baylor College Of Medicine | Enhanced gene expression system |
| US7004940B2 (en) | 2002-10-10 | 2006-02-28 | Ethicon, Inc. | Devices for performing thermal ablation having movable ultrasound transducers |
| WO2005118865A2 (en) * | 2004-05-28 | 2005-12-15 | St. Jude Children's Research Hospital | Diagnosis and treatment of drug resistant leukemia |
| EP1885187B1 (en) * | 2005-05-13 | 2013-09-25 | Novartis AG | Methods for treating drug resistant cancer |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| EP3043181B1 (en) | 2008-01-15 | 2020-04-08 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| WO2012177624A2 (en) | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| US9181535B2 (en) | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| BR112015016282A2 (en) * | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals, Inc. | crenolanib for treatment of mutated flt3 proliferative disorders |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| US20160272720A1 (en) * | 2013-11-06 | 2016-09-22 | Memorial Sloan-Kettering Cancer Center | Compositions and Methods for the Treatment of Acute Myeloid Leukemias and Myelodysplastic Syndromes |
-
2017
- 2017-09-20 ES ES17853809T patent/ES3033182T3/es active Active
- 2017-09-20 CA CA3034643A patent/CA3034643A1/en active Pending
- 2017-09-20 AU AU2017332721A patent/AU2017332721B2/en not_active Ceased
- 2017-09-20 JP JP2019537032A patent/JP7466308B2/ja active Active
- 2017-09-20 EP EP17853809.6A patent/EP3515559B1/en active Active
- 2017-09-20 US US16/331,712 patent/US11136409B2/en active Active
- 2017-09-20 WO PCT/US2017/052506 patent/WO2018057618A1/en not_active Ceased
-
2022
- 2022-06-10 JP JP2022094297A patent/JP2022116353A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534321A5 (https=) | ||
| US20230034473A1 (en) | Methods of treating fibroblast growth factor 19-mediated cancers and tumors | |
| JP6912538B2 (ja) | 血中循環腫瘍細胞に関する方法およびアッセイ | |
| US11952634B2 (en) | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer | |
| Gavine et al. | Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models | |
| Hulanicka et al. | Plasma miRNAs as potential biomarkers of chronic degenerative valvular disease in Dachshunds | |
| JP2015530072A (ja) | ゲムシタビン療法による乳癌の治療方法 | |
| JP2014514278A (ja) | アントラサイクリン療法を用いて乳癌を処置する方法 | |
| JP2008536480A5 (https=) | ||
| Moschetta et al. | Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1α in canine malignant mammary tumors | |
| JP2018532978A (ja) | 最適な癌療法のためのＦＲ−αおよびＧＡＲＴタンパク質の定量 | |
| JP2008512984A5 (https=) | ||
| US20220341936A1 (en) | Pd-l1 as a predictive marker for therapy in cancer | |
| WO2015095686A1 (en) | Assays and methods relating to the treatment of melanoma | |
| JP2008530575A (ja) | Ｃｈｋ１阻害薬に対する応答性を判定する方法 | |
| CN119193825A (zh) | 选择针对癌症患者的治疗的方法 | |
| US20120156681A1 (en) | Composition for diagnosis of liver metastasis of colorectal cancer and the use thereof | |
| Wada et al. | mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer | |
| KR102222523B1 (ko) | 약물 반응성 예측용 조성물 및 이의 용도 | |
| Moradi-Marjaneh et al. | The clinical impact of quantitative cell-free DNA, KRAS, and BRAF mutations on response to anti-EGFR treatment in patients with metastatic colorectal cancer | |
| Sato et al. | Nationwide multi-centric prospective study for the identification of biomarkers to predict the treatment responses of nivolumab through comprehensive analyses of pretreatment plasma exosome mRNAs from head and neck cancer patients (BIONEXT study) | |
| JP6478417B2 (ja) | 大腸癌患者の生存を予測及び改善するための方法 | |
| KR102222520B1 (ko) | 약물 반응성 예측용 조성물 및 이의 용도 | |
| JP2020522500A (ja) | 胃癌治療成績の予測方法 | |
| Sato et al. | Prospective exploration of a prognostic biomarker of nivolumab for head and neck cancer patients (BIONEXT) |